Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“A major factor affecting the loss of apoptotic function is p53 gene mutation (see Figure 6), which is observed in about a half of all cancers (Hollstein et al., 1991; Soussi, 2000).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
Background
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Items 301–400 of 1,004
Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines
Michaelis, M., Kleinschmidt, M. C., Barth, S., Rothweiler, F., Geiler, J., Breitling, R., Mayer, B., Deubzer, H. E., Witt, O., Kreuter, J., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.08.013 · Cited by 110
Ang, C. Y., Tan, S. Y., & Zhao, Y. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00164h · Cited by 119
Santos, C. R., Rodriguez-Pinilla, M. S., Vega, F. M. D. L., Rodríguez‐Peralto, J. L., Blanco, S., Sevilla, A., Valbuena, A., Hernández, T., van Wijnen, A. J., Li, F., et al. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0212 · Cited by 116
The development of platinum compounds and their possible combination
Pasetto, L. M., D'Andrea, M. R., Brandes, A. A., Rossi, E. G., & Monfardini, S. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.02.003 · Cited by 109
Tumiati, M., Hietanen, S., Hynninen, J., Pietilä, E. A., Färkkilä, A., Kaipio, K., Roering, P., Huhtinen, K., Alkodsi, A., Li, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3770 · Cited by 117
Zhou, J., Hu, S.-E., Tan, S.-H., Cao, R., Chen, Y., Xia, D., Zhu, X., Yang, X., Ong, C. N., & Shen, H. (2012) · Autophagy · doi:10.4161/auto.18721 · Cited by 115
Aurora-A Regulation of Nuclear Factor-κB Signaling by Phosphorylation of IκBα
Briassouli, P., Chan, F., Savage, K., Reis-Filho, J. S., & Linardopoulos, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2272 · Cited by 112
Ma, J., Wang, Q., Huang, Z., Yang, X., Nie, Q., Hao, W., Wang, P. G., & Wang, X. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00433 · Cited by 107
The Role of DNA Polymerase η in Translesion Synthesis Past Platinum–DNA Adducts in Human Fibroblasts
Bassett, E., King, N. M., Bryant, M. F., Hector, S., Pendyala, L., Chaney, S. G., & Cordeiro-Stone, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1328 · Cited by 107
Nuclear EGFR is required for cisplatin resistance and DNA repair.
Hsu, S.-C., Miller, S. A., Wang, Y., & Hung, M. (2009) · PubMed Central · Cited by 107
Sui, X., Luo, C., Wang, C., Zhang, F., Zhang, J., & Guo, S. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.03.010 · Cited by 109
Park, B. H., Lim, J. E., Jeon, H. G., Seo, S. I., Lee, H. M., Choi, H. Y., Jeon, S. S., & Jeong, B. C. (2016) · Oncotarget · doi:10.18632/oncotarget.11563 · Cited by 106
“Curcumin and cisplatin promote reactive oxygen species (ROS) generation in 253J-Bv and T24 cells ROS plays important roles in apoptosis of cancer cells in response to DNA damage.”
BackgroundInfluentialGlucose deprivation-induced metabolic oxidative stress and cancer therapy
Spitz, D. R., Simons, A. L., Mattson, D., & Dornfeld, K. J. (2009) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.55133 · Cited by 106
Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy
Aziz, K., Nowsheen, S., Pantelias, G. E., Iliakis, G. E., Gorgoulis, V. G., & Georgakilas, A. G. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.010 · Cited by 116
Etemadmoghadam, D., George, J., Cowin, P. A., Cullinane, C., Kansara, M., Australian Ovarian Cancer Study Group, Gorringe, K. L., Smyth, G. K., & Bowtell, D. D. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015498 · Cited by 105
Abbosh, P. H., Montgomery, J. S., Starkey, J. A., Novotny, M., Zuhowski, E. G., Egorin, M. J., Moseman, A. P., Golas, A., Brannon, K. M., Balch, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3575 · Cited by 105
Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery
Guven, A., Rusakova, I. A., Lewis, M. T., & Wilson, L. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.060 · Cited by 111
Li, Y., Ye, Z., Lai, W., Rao, J., Huang, W., Zhang, X., Yao, Z., & Lou, T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00178 · Cited by 116
“Cisplatin is one of the most efficient and widely used anticancer chemotherapy drugs in the clinic for the treatment of bladder cancer, non-small cell lung cancer and other solid tumors (Siddik, 2003).”
BackgroundNrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma.
Bao, L.-J., Jaramillo, M. C., Zhang, Z.-B., Zheng, Y.-X., Yao, M., Zhang, D. D., & Yi, X.-F. (2014) · Europe PMC (PubMed Central) · Cited by 131
Khaleque, A., Bharti, A. K., Sawyer, D. B., Gong, J., Benjamin, I. J., Stevenson, M. A., & Calderwood, S. K. (2005) · Oncogene · doi:10.1038/sj.onc.1208798 · Cited by 115
Müller, A., Sonkoly, E., Eulert, C., Gerber, P. A., Kubitza, R., Schirlau, K., Franken‐Kunkel, P., Poremba, C., Snyderman, C. H., Klotz, L., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21514 · Cited by 104
Eckstein, N., Servan, K., Girard, L., Cai, D., von Jonquieres, G., Jaehde, U., Kassack, M. U., Gazdar, A. F., Minna, J. D., & Royer, H.-D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706287200 · Cited by 102
When Oxidative Stress Meets Epigenetics: Implications in Cancer Development
García-Guede, Á., Vera, O., & de Cáceres, I. I. (2020) · Antioxidants · doi:10.3390/antiox9060468 · Cited by 117
Bi, G., Liang, J., Zhao, M., Zhang, H., Jin, X. Y., Lu, T., Zheng, Y., Bian, Y., Chen, Z., Huang, Y., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.020 · Cited by 108
“CDDP exerts anti-cancer effects mainly by interacting with DNA to form mostly intrastrand cross-link adducts, which activates a series of signaling pathways and cell death.(8) Although numerous clinical trials have verified the superiority of PEM to other chemotherapeutic agents, few studies have explored the mechanis…”
Pyndiah, S., Tanida, S., Ahmed, K. M., Cassimere, E. K., Choe, C., & Sakamuro, D. (2011) · Science Signaling · doi:10.1126/scisignal.2001556 · Cited by 118
Farrand, L., Byun, S., Kim, J. Y., Im-Aram, A., Lee, J. H., Lim, S., Lee, K. W., Suh, J., Lee, H. J., & Tsang, B. K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.487686 · Cited by 110
Han, Y., Yin, W., Li, J., Zhao, H. L., Zha, Z., Ke, W., Wang, Y., He, C., & Ge, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.019 · Cited by 103
“However, the related side effects and drug resistance strictly limit its further clinical applications [2,3].”
BackgroundMollaei, M., Hassan, Z. M., Khorshidi, F., & Langroudi, L. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101056 · Cited by 131
Gielecińska, A., Kciuk, M., Yahya, E. B., Ainane, T., Mujwar, S., & Kontek, R. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189024 · Cited by 123
Hung, J., Lu, Y., Wang, Y.-C., Ma, Y., Wang, D.-S., Kulp, S. K., Muthusamy, N., Byrd, J. C., Cheng, A., & Chen, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2621 · Cited by 102
Zhao, Y., Woods, J. A., Farrer, N. J., Robinson, K. S., Prachařová, J., Kašpárková, J., Nováková, O., Li, H., Salassa, L., Pizarro, A. M., et al. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201300374 · Cited by 101
Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells
Li, Y., Chen, X., Yang, Q., Chen, J., Huang, Q., Yao, L., Ding, Y., Wu, J., Zhang, P., Tang, D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00949 · Cited by 104
“The mechanism of acquired cisplatin resistance is multifactor and has been attributed to acquire GSH, an important intracellular antioxidant (35).”
BackgroundBelyanskaya, L. L., Hopkins-Donaldson, S., Kurtz, S., Simões‐Wüst, A. P., Yousefi, S., Simon, H., Stahel, R. A., & Zangemeister‐Wittke, U. (2005) · International Journal of Cancer · doi:10.1002/ijc.21242 · Cited by 113
Mo, D., Fang, H., Niu, K., Liu, J., Wu, M., Li, S., Zhu, T., Aleskandarany, M. A., Arora, A., Lobo, D. N., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2361 · Cited by 101
“Also, constitutive activation of DNA damage response (DDR) pathways owing to elevated expression of DNA repair genes also contributes to chemo resistance by efficient reversal of cisplatin-DNA adducts (6).”
BackgroundMdmX is a substrate for the deubiquitinating enzyme USP2a
Allende-Vega, N., Sparks, A., Lane, D. P., & Saville, M. K. (2010) · Oncogene · doi:10.1038/onc.2009.330 · Cited by 100
Ma, L., Ma, R., Wang, Y., Zhu, X. A., Zhang, J., Chan, H. C., Chen, X., Zhang, W., Chiu, S.-K., & Zhu, G. (2015) · Chemical Communications · doi:10.1039/c4cc10409a · Cited by 105
Siddiqui-Jain, A., Bliesath, J. R., Macalino, D., Omori, M., Huser, N. H., Streiner, N., Ho, C., Anderes, K. L., Proffitt, C., O’Brien, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0613 · Cited by 119
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy
Benkafadar, N., Menardo, J., Bourien, J., Nouvian, R., François, F., Decaudin, D., Maiorano, D., Puel, J., & Wang, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606230 · Cited by 112
“Cisplatin (cis-diammine dichloroplatinum(II); CDDP) is a highly effective and widely used chemotherapeutic agent for the treatment of different types of human tumors, particularly solid tumors (Siddik, 2003; Wang & Lippard, 2005).”
BackgroundAnticancer drug discovery from Chinese medicinal herbs
Huang, M., Zhang, L., Ding, J., & Lu, J. (2018) · Chinese Medicine · doi:10.1186/s13020-018-0192-y · Cited by 117
Cavill, R., Kamburov, A., Ellis, J. K., Athersuch, T. J., Blagrove, M. S. C., Herwig, R., Ebbels, T. M. D., & Keun, H. C. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001113 · Cited by 114
Mitaplatin Increases Sensitivity of Tumor Cells to Cisplatin by Inducing Mitochondrial Dysfunction
Xue, X., You, S., Zhang, Q., Wu, Y. F., Zou, G.-Z., Wang, P. C., Zhao, Y.-L., Xu, Y., Jia, L., Zhang, X., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200571k · Cited by 105
Gong, Q., Shi, W. S., Li, L., & Ma, H. (2015) · Chemical Science · doi:10.1039/c5sc03600c · Cited by 99
Emerging drugs for high-grade osteosarcoma
Hattinger, C. M., Pasello, M., Ferrari, S., Picci, P., & Serra, M. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.505603 · Cited by 99
Dominelli, B., Correia, J. D. G., & Kühn, F. E. (2018) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2018.04.023 · Cited by 99
DNA repair inhibition: a selective tumour targeting strategy
Madhusudan, S., & Hickson, I. D. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.09.004 · Cited by 112
Chen, C. K. J., Zhang, J., Aitken, J. B., & Hambley, T. W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401218n · Cited by 99
Yan, X., Fraser, M. E., Qiu, Q., & Tsang, B. K. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.033 · Cited by 106
Novel platinum(IV) complexes induce rapid tumor cell death in vitro
Kaluđerović, G. N., Miljković, D. M., Momčilović, M. B., Djinović, V. M., Stojković, M. M., Sabo, T. J., & Trajković, V. (2005) · International Journal of Cancer · doi:10.1002/ijc.21080 · Cited by 100
EndoG is dispensable in embryogenesis and apoptosis
David, K. K., Sasaki, M., Yu, S.-W., Dawson, T. M., & Dawson, V. L. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401787 · Cited by 96
Sava, G., Jaouen, G., Hillard, E. A., & Bergamo, A. (2012) · Dalton Transactions · doi:10.1039/c2dt30075c · Cited by 97
Cytotoxicity of Gold(I) N‐Heterocyclic Carbene Complexes Assessed by Using Human Tumor Cell Lines
Weaver, J., Gaillard, S., Toye, C., Macpherson, S., Nolan, S. P., & Riches, A. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201100321 · Cited by 98
Surowiak, P., Materna, V., Kaplenko, I., Spaczyński, M., Dietel, M., Lage, H., & Zabel, M. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-1228-0 · Cited by 98
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
Jiang, M., Pabla, N., Murphy, R. F., Yang, T., Yin, X.-M., Degenhardt, K., White, E., & Dong, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606928200 · Cited by 97
Ruthenium(II) Metallo‐intercalators: DNA Imaging and Cytotoxicity
Gill, M. R., Derrat, H. S., Smythe, C., Battaglia, G., & Thomas, J. A. (2011) · ChemBioChem · doi:10.1002/cbic.201000782 · Cited by 101
Suntharalingam, K., Johnstone, T. C., Bruno, P. M., Wei, L., Hemann, M. T., & Lippard, S. J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4075375 · Cited by 102
A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex
Novohradský, V., Zerzánková, L., Štěpánková, J., Kisova, A., Kostrhunová, H., Liu, Z., Sadler, P. J., Kašpárková, J., & Brabec, V. (2014) · Metallomics · doi:10.1039/c4mt00112e · Cited by 97
Lanthanide porphyrinoids as molecular theranostics
Jin, G., Chau, C. V., Arambula, J. F., Gao, S. W., Sessler, J. L., & Zhang, J. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00275b · Cited by 100
Necroptosis-Inducing Rhenium(V) Oxo Complexes
Suntharalingam, K., Awuah, S. G., Bruno, P. M., Johnstone, T. C., Wang, F., Wei, L., Zheng, Y., Page, J. E., Hemann, M. T., & Lippard, S. J. (2015) · Journal of the American Chemical Society · doi:10.1021/ja511978y · Cited by 104
Shi, R., Huang, Q., Zhu, X., Ong, Y. B., Zhao, B., Lu, J., Ong, C. N., & Shen, H. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0638 · Cited by 105
Cancer stem cells as a therapeutic target in bladder cancer
Aghaalikhani, N., Rashtchizadeh, N., Shadpour, P., Allameh, A., & Mahmoodi, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26916 · Cited by 104
“The 5‐year survival rate for patients suffering from MIBC is estimated to be about 50% (Nadal & Bellmunt, 2014) and 15–20% for ovarian cancer (Siddik, 2003).”
BackgroundCisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy
Domínguez-Ríos, R., Sánchez-Ramírez, D. R., Ruiz-Saray, K., Oceguera-Basurto, P. E., Almada, M., Juárez, J., Zepeda‐Moreno, A., Toro‐Arreola, A. D., Topete, A., & Daneri‐Navarro, A. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.03.011 · Cited by 101
A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1
Luca, A. D., Parker, L. J., Ang, W. H., Rodolfo, C., Gabbarini, V., Hancock, N. C., Palone, F., Mazzetti, A. P., Menin, L., Morton, C. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903297116 · Cited by 97
Bamias, A., Karina, M., Papakostas, P., Kostopoulos, I. S., Bobos, M., Vourli, G., Samantas, E., Christodoulou, C., Pentheroudakis, G. E., Pectasides, D. G., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1256-6 · Cited by 96
Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding
Soni, H., Kaminski, D., Gangaraju, R., & Adebiyi, A. (2018) · Renal Failure · doi:10.1080/0886022x.2018.1456938 · Cited by 101
“Cisplatin promotes cytotoxicity by forming covalent bonds with nucleophilic purine-N(7) sites in DNA, thereby impeding DNA replication and transcription, and inducing cell death [3].”
BackgroundEndo, H., Yano, M., Okumura, Y., & Kido, H. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.550 · Cited by 95
“Several studies have found that mitochondria might be a direct and important target of cisplatin in sensitive cells.(32,33) We studied the effects of ibuprofen on the depolarization of mitochondrial membranes”
BackgroundInterfaces between cellular responses to DNA damage and cancer immunotherapy
Pilger, D., Seymour, L. W., & Jackson, S. P. (2021) · Genes & Development · doi:10.1101/gad.348314.121 · Cited by 95
Yang, Y., Kim, J., Lee, K., & Choi, J. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.08.031 · Cited by 92
Wangpaichitr, M., Sullivan, E. J., Theodoropoulos, G., Wu, C., You, M., Feun, L. G., Lampidis, T. J., Kuo, M. T., & Savaraj, N. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0599 · Cited by 96
Gaspari, F., Cravedi, P., Mandalà, M., Perico, N., León, F. R. D., Stucchi, N., Ferrari, S., Labianca, R., Remuzzi, G., & Ruggenenti, P. L. (2010) · Nephron Clinical Practice · doi:10.1159/000312879 · Cited by 106
The emerging role of microRNAs in resistance to lung cancer treatments
MacDonagh, L., Gray, S. G., Finn, S. P., Cuffe, S. D., O'Byrne, K. J., & Barr, M. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.009 · Cited by 103
A Cytotoxic Ruthenium Tris(Bipyridyl) Complex that Accumulates at Plasma Membranes
Zava, O., Zakeeruddin, S. M., Danelon, C., Vogel, H., Grätzel, M., & Dyson, P. J. (2009) · ChemBioChem · doi:10.1002/cbic.200900013 · Cited by 93
A view on multi-action Pt(IV) antitumor prodrugs
Ravera, M., Gabano, E., McGlinchey, M. J., & Osella, D. (2019) · Inorganica Chimica Acta · doi:10.1016/j.ica.2019.04.025 · Cited by 99
Cellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Cai, J., Yang, C., Yang, Q., Ding, H., Jia, J., Guo, J., Wang, J., & Wang, Z. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.39 · Cited by 96
Ehlén, Å., Brennan, D. J., Nodin, B., O’Connor, D. P., Eberhard, J., Alvarado-Kristensson, M., Jeffrey, I. B., Manjer, J., Brändstedt, J., Uhlén, M., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-78 · Cited by 94
Surnar, B., Sharma, K., & Jayakannan, M. (2015) · Nanoscale · doi:10.1039/c5nr04963f · Cited by 93
Wang, S.-F., Chen, M.-S., Chou, Y.-C., Ueng, Y.-F., Yin, P.-H., Yeh, T.-S., & Lee, H.-C. (2016) · Oncotarget · doi:10.18632/oncotarget.12356 · Cited by 93
“glutathione (GSH), increased DNA damage repair, and the inhibition of apoptosis [11].”
BackgroundCurcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells
Mendonça, L. M., Machado, C. D. S., Teixeira, C. C. C., de Freitas, L. A. P., Bianchi, M. D. L. P., & Antunes, L. M. G. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.09.011 · Cited by 98
Microbiota–drug interactions: Impact on metabolism and efficacy of therapeutics
Wilkinson, E. M., Ilhan, Z. E., & Herbst‐Kralovetz, M. M. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.03.012 · Cited by 102
Next-generation DNA damage sequencing
Mingard, C., Wu, J., McKeague, M., & Sturla, S. J. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00647e · Cited by 92
Wexselblatt, E., Yavin, E., & Gibson, D. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201300640 · Cited by 92
Roudier, E., Mistafa, O., & Stenius, U. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0352 · Cited by 92
Katagiri, D., Hamasaki, Y., Doi, K., Negishi, K., Sugaya, T., Nangaku, M., & Noiri, E. (2015) · Kidney International · doi:10.1038/ki.2015.327 · Cited by 99
Muguruma, M., Teraoka, S., Miyahara, K., Ueda, A., Asaoka, M., Okazaki, M., Kawate, T., Kuroda, M., Miyagi, Y., & Ishikawa, T. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.075 · Cited by 105
Pan, Y., Zhang, Q., Atsaves, V., Yang, H., & Claret, F. X. (2012) · Oncogene · doi:10.1038/onc.2012.294 · Cited by 91
Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer
Cole, C. L., Lau, S., Backen, A. C., Clamp, A. R., Rushton, G., Dive, C., Hodgkinson, C. L., McVey, R. J., Kitchener, H. C., & Jayson, G. C. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.5.12585 · Cited by 89
Novak, M., Žegura, B., Modic, B., Heath, E., & Filipič, M. (2017) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2017.05.115 · Cited by 91
Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells
Kalayda, G. V., Wagner, C. H., & Jaehde, U. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.07.010 · Cited by 90
Interactions of anticancer drugs with biomembranes: What can we learn from model membranes?
Bourgaux, C., & Couvreur, P. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.012 · Cited by 103
Tissue Platinum Concentration and Tumor Response in Non–Small-Cell Lung Cancer
Kim, E. S., Lee, J. J., He, G., Chow, C.-W. B., Fujimoto, J., Kalhor, N., Swisher, S. G., Wistuba, I. I., Stewart, D. J., & Siddik, Z. H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.8120 · Cited by 91
Self-citationGasch, C., Ffrench, B., O’Leary, J. J., & Gallagher, M. F. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0601-3 · Cited by 102
“However, Wang et al. [81] have demonstrated that NER protein levels are unrelated to platinum-sensitivity in ovarian cancer.”
BackgroundInfluentialMoruno-Manchon, J. F., Koellhoffer, E. C., Gopakumar, J., Hambarde, S., Kim, N., McCullough, L. D., & Tsvetkov, A. S. (2017) · Aging · doi:10.18632/aging.101282 · Cited by 89
“Cisplatin, another anti-tumor agent, cross-links DNA and, therefore, promotes cytotoxicity [28].”
Low‐intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin
Watanabe, Y., Aoi, A., Horie, S., Tomita, N., Mori, S., MORIKAWA, H., Matsumura, Y., Vassaux, G., & Kodama, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00989.x · Cited by 90
Billecke, C., Finniss, S., Tahash, L., Miller, C. G., Mikkelsen, T., Farrell, N. P., & Bögler, O. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-004 · Cited by 90
The role of microbiota in cancer therapy
Perez-Chanona, E., & Trinchieri, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.01.003 · Cited by 90
Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer
Aranda, F., Bloy, N., Pesquet, J., Petit, B., Chaba, K., Sauvat, A., Kepp, O., Khadra, N., Enot, D., Pfirschke, C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.234 · Cited by 89
Therapeutic Perspectives of Molecules from Urtica dioica Extracts for Cancer Treatment
Esposito, S., Bianco, A., Russo, R., Maro, A. D., Isernia, C., & Pedone, P. V. (2019) · Molecules · doi:10.3390/molecules24152753 · Cited by 106
“dioica methanolic extract from the aerial parts demonstrated hepatoprotective and nephroprotective activities against cisplatin-induced [74,75] toxicity, most likely due to increasing antioxidant defense mechanisms, in fact, this extract has been shown to increase the activities of catalase (CAT) and superoxide dismut…”
BackgroundPotential Therapeutic Implications of Caffeic Acid in Cancer Signaling: Past, Present, and Future
Alam, M., Ashraf, G. M., Sheikh, K., Khan, A., Ali, S., Ansari, M. M., Adnan, M., Pasupuleti, V. R., & Hassan, M. I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.845871 · Cited by 94
“CA is an inhibitor of glutathione Stransferase and glutathione reductase that are the catalytic enzymes of GTH (Figure 2) (Siddik, 2003; Islam et al., 2017).”
MethodPiskareva, O., Harvey, H. M., Nolan, J., Conlon, R., Alcock, L., Buckley, P. G., Dowling, P., Henry, M. A., O’Sullivan, F., Bray, I. M., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.004 · Cited by 101
Drąg, M., Surowiak, P., Drąg‐Zalesińska, M., Dietel, M., Lage, H., & Oleksyszyn, J. (2009) · Molecules · doi:10.3390/molecules14041639 · Cited by 89
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.